| Document |
Document Title |
|
WO/1999/056791A1 |
A radiolabeled tris(2-mercaptobenzyl)amine complex is provided. Complexes containing analogs of the tris(2-mercaptobenzyl)amine ligand are also described. The complex is useful for diagnostic or therapeutic applications which involve loc...
|
|
WO/1999/056765A1 |
The present invention provides compounds of Formula (I), pharmaceutical compositions comprising a compound of Formula (I), and methods of treatment of stroke; inflammatory diseases such as rheumatoid arthritis or inflammatory bowel disea...
|
|
WO/1999/057098A2 |
A class of substituted $g(b)-amino acids are potent inhibitors of methionine aminopeptidase type 2 (MetAP2) and are thus useful in inhibiting angiogenesis and disease conditions which depend upon angiogenesis for their development such a...
|
|
WO/1999/055663A1 |
The present invention relates to compounds which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well ...
|
|
WO/1999/055673A1 |
The invention relates to novel arylphenyl-substituted cyclic keto enols of formula (I), wherein X represents halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkyl halide, halogenalkoxy, halogenalkenyloxy, nit...
|
|
WO/1999/055668A1 |
3-Arylphenyl sulfide derivatives represented by general formula (I) and insecticides and miticides containing these derivatives as the active ingredient, wherein R represents C¿2?-¿6? alkyl, C¿2?-¿6? alkenyl, C¿2?-¿6? alkynyl, etc....
|
|
WO/1999/054296A1 |
A process for producing a compound represented by formula (I) which comprises reacting a compound represented by formula (V) with a compound represented by formula (VI) in the presence of a base; a process for producing a compound repres...
|
|
WO/1999/054283A1 |
The present invention describes the design, synthesis and therapeutic use of a variety of novel inhibitors of polyamine transport. The main feature of this class of transport inhibitors is to incorporate a linker or side chain that preve...
|
|
WO1999024460B1 |
N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inf...
|
|
WO/1999/051564A1 |
This invention relates to new propanolamine derivatives or salts thereof represented by general formula (I), wherein each symbol is as defined in the specification or salts thereof which are $g(b)¿3? adrergenic receptor agonists and the...
|
|
WO/1999/051276A1 |
There are provided methods for the treatment or diagnosis of cancer in a mammal, including the step of administering to the mammal an effective amount of a substantially tin-free solution of ?188¿Re(V)-2,3-dimercaptosuccinic acid, ?186Â...
|
|
WO/1999/050238A1 |
Compounds having a urea structure as the basic structure and carrying sulfur and amide bonds in side chains. It has been found out that these compounds have pharmacological effects, in particular, a TNF-$g(a) production inhibitory effect...
|
|
WO/1999/050237A1 |
Sulfonamide derivatives represented by general formula (1) or salts thereof, wherein A represents nitrogen, -CH=, etc.; Z represents oxygen, etc.; Ar?1¿ represents aryl, etc.; Ar?2¿ represents alkyl, etc.; R?a¿ represents hydrogen, et...
|
|
WO/1999/050239A2 |
The invention concerns novel heteroethynylene compounds of general formula (I) and their use in pharmaceutical compositions for use in human or veterinary medicine (dermatologic, rheumatic, respiratory, cardiovascular and ophthalmologic ...
|
|
WO/1999/048865A1 |
Compounds of general formula (I), wherein R represents a straight or branched chain alkyl group containing from 1 to 16 carbon atoms, pharmaceutically acceptable salts thereof and/or optical isomers thereof have an immunostimulating effe...
|
|
WO/1999/048851A2 |
The invention relates to processes for the preparation of compounds of formula (I), wherein R?1¿ and R?2¿ are as defined in the description.
|
|
WO/1999/048859A1 |
There is provided novel aryloxyanilides and related compounds of formula (I), wherein R?1¿ is -OR, -CO¿2?R, or halogen with R being C¿1-4? alkyl; R?2¿ is R, cyclopropyl, C¿2-4? alkenyl or -CH¿2?OR; and X is O, S, CH¿2?, NR, SO, SO...
|
|
WO/1999/048877A1 |
The invention relates to novel substituted 2,4-diamino-1,3,5-triazines of formula (I) in which n represents 0, 1 or 2, R?1¿ represents H or C¿1?-C¿6?-alkyl for example, R?2¿ represents H, formyl, C¿1?-C¿6?-alkyl, C¿1?-C¿6?-alkyl ...
|
|
WO/1999/048869A1 |
The invention relates to new aryl phenyl substituted ketoenols of formula (I), where X is halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkyl sulfinyl, alkyl sulfonyl, halogen alkyl, halogen alkoxy, halogen alkenyloxy, nitro, cyano or p...
|
|
WO/1999/047508A1 |
Compounds of formula (I), pharmaceutically acceptable salts or $i(in vivo) hydrolysable esters thereof, wherein: Ring X is phenyl or a six membered heteroaryl ring containing one or two ring nitrogens where said nitrogens are optionally ...
|
|
WO/1999/047474A1 |
This invention relates to a novel, inventive process for the preparation of biphenyls or aromatic olefins by coupling reactions of the Suzuki coupling and Heck coupling type, using allylpalladium catalysts of the $g(m)-halo(triisopropylp...
|
|
WO/1999/047498A1 |
A substrate for solid phase synthesis of formula (a) is disclosed. Also disclosed are processes for preparing the substrate and intermediates useful therein. Among the novel intermediates are compounds of formula (VI), wherein t is 0 or ...
|
|
WO/1999/046240A2 |
Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors of Formula (I) or a pharmaceutically acceptable salt thereof, wherein all substituents are described in the specification.
|
|
WO/1999/046232A1 |
Compounds represented by general formula (I), nontoxic salts thereof or hydrates of the same; and peroxisome proliferator-activated receptor regulating agents containing the same as the active ingredient, wherein each symbol is as define...
|
|
WO/1999/044988A2 |
The invention relates to a method for preparing sulfanyl-type endothelin receptor antagonists of general formula (I) wherein R?1¿ represents hydroxy, alkoxy, sulfonamidyl, amino; R?2¿ represents alkyl, aryl or heteroaryl, optionally su...
|
|
WO/1999/044618A1 |
The use of a compound of formula (I) wherein: ring C is phenyl or carbon-linked heteroaryl selected from pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl; and wherein said phenyl or heteroaryl is substituted as defined herein; A-B is sele...
|
|
WO/1999/043642A1 |
Phenylalanine derivatives of formula (1) are described: wherein R is a carboxylic acid or a derivative thereof; L?1¿ is a linker atom or group; Ar is an optionally substituted aromatic group; and the salts, solvates, hydrates and N-oxid...
|
|
WO/1999/043649A1 |
The invention relates to new arylphenyl-substituted cyclic keto-enols of the formula (I), where X is halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkyl sulfinyl, alkyl sulfonyl, halogen alkyl, halogen alkoxy, halogen alkenyloxy, nitro,...
|
|
WO/1999/043644A1 |
Novel $g(a)-amino acid amides of formula (I) as well as possible isomers and mixtures of isomers thereof, wherein the substituents are defined as follows: n is the number zero or one; R¿1? is optionally substituted alkyl, alkenyl, alkyn...
|
|
WO/1999/042097A1 |
The present invention relates to methods of using peptide-like compounds, e.g., aminocarboxylic acid amide derivatives, to bias the immune system toward producing, enhancing, or maintaining a polarized Th1 response, and to methods for tr...
|
|
WO/1999/042429A1 |
The present invention provides compounds of general formula (I) or (II): wherein R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?, and R¿7? have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as w...
|
|
WO/1999/042098A1 |
The present invention relates to peptide-like compounds, e.g. aminocarboxylic acid amide derivatives, and to methods of using same in the field of general health care, for example, to improve resistance to stress, improve production of d...
|
|
WO/1999/042436A1 |
Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes inc...
|
|
WO/1999/042457A2 |
The invention relates to novel substituted alkoxycarbonyl compounds of formula (I), wherein n stands for 0 or 1; Ar stands for an optionally substituted monocyclic or bicyclic saturated or optionally partially- unsaturated carbocyclic or...
|
|
WO/1999/042116A1 |
The present invention is directed to novel disulfides and thiols that are of up to about eighteen amino acids. One example is a compound of the formula (1): A-B-C-S-S-D-E-F, wherein A and F are selected from the group consisting of hydro...
|
|
WO/1999/042099A1 |
The present invention relates to peptide-like compounds, e.g. aminocarboxylic acid amide derivatives, and to methods of using same to stimulate cells of the immune system, bone marrow and other organs. The present compounds can be used t...
|
|
WO1998022435A9 |
The invention concerns a reagent and a family of compounds. The reagent contains by successive or simultaneous addition: a material of formula RfH, a silicophilic base, a trivalent nitrogenous derivative containing no hydrogen and at lea...
|
|
WO/1999/041231A1 |
Novel amidino derivatives represented by general formula (I) which have an inhibitory effect on blood coagulation factor VIIa and are useful as preventives and/or remedies for various vascular lesions associating accelerated coagulation ...
|
|
WO/1999/041224A1 |
The present invention relates to inhibitors of COX-2, compositions which contain such compounds and methods of use. The compounds are represented by formula (I) and include pharmaceutically acceptable salts and esters thereof.
|
|
WO/1999/041227A1 |
The present invention relates to a class of substituted amino acids, pharmaceutical compositions and methods of treating neurological and neuropsychiatric disorders.
|
|
WO/1999/040064A1 |
The invention relates to compounds of formula (I) in which the symbols have the meanings given in the description. The compounds have excellent antiarrhythmic properties and comprise a cardioprotective component. The inventive compounds ...
|
|
WO/1999/040066A1 |
A process for the preparation of S-alkylcysteines of formula (I) wherein R is a lower or branched C¿1?-C¿4? alkyl group; by S-alkylation of cysteines with dialkylcarbonates
|
|
WO/1999/039704A1 |
Compounds of formula (I) are antibacterials: wherein R¿1? represents hydrogen, or C¿1?-C¿6? alkyl or C¿1?-C¿6? alkyl substituted by one or more halogen atoms; R¿2? represents a group R¿10?-(X)¿n?-(ALK)¿M?- wherein R¿10? represe...
|
|
WO/1999/038821A2 |
The invention concerns a novel agent for transferring nucleic acids into cells. Said agent is particularly characterised in that it comprises one or several disulphide bonds sensitive to reducing conditions. The invention also concerns c...
|
|
WO/1999/038846A1 |
Disclosed are methods of suppressing the immune system in a subject in need of immune system suppression. The method comprises administering to the subject an effective amount of a compound represented by Structural Formulas (I, II, III ...
|
|
WO/1999/037306A1 |
The invention includes new substituted tetracycline-type compounds that exhibit significant antibacterial activity, including against both gram-positive and gram-negative bacteria. It has been found that compounds of the invention are hi...
|
|
WO/1999/037603A1 |
Compounds of formula (I), wherein: A¿1? and A¿2? each represent independently of one other an aryl or a heteroaryl radical; and A¿1? where appropriate is substituted with substituent (R¿3a?)¿n1? and A¿2? where appropriate with subs...
|
|
WO/1999/037307A1 |
The invention includes new substituted tetracycline compounds that exhibit significant antibacterial activity, including gram-positive and gram-negative bacteria, and gram-positive and gram-negative tetracycline sensitive and tetracyclin...
|
|
WO/1999/036383A1 |
A process for producing substances capable of inducing apoptosis characterized by involving the step of heating at least one compound selected from among the following compounds (a) to (d), provided that uronic acid and/or uronic acid de...
|
|
WO/1999/036393A1 |
The present invention relates to a pharmaceutical composition comprising as an active ingredient a compound of formula (I), wherein Ring A is an aromatic or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene, lower alkenylene, -O...
|
